Public market insider buying at Knight Therapeutics (T:GUD)

Sime Armoyan, a 10% Holder, acquired 34,700 Common Shares on a control or direction basis for registered holder Armco Alberta Inc. at prices ranging from $4.384 to $4.400 between September 13th, 2023 and September 15th, 2023. This represents a $152,246 investment into the company's shares and an account share holdings change of 0.3%.

Knight Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is engaged in the development, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It also finances other life sciences companies, invests in venture capital funds and develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's products include EXELON, BIJUVA, IMVEXXY, IBSRELA, TRELSTAR Prostate, TRELSTAR Endometriosis, Nerlynx, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex, Probuphine, Movantik and Neuragen. It owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. The Company's subsidiary includes Knight Therapeutics International S.A., which develops pharmaceuticals, including those used to treat neglected tropical diseases and rare pediatric diseases.